Trials / Completed
CompletedNCT05011669
The Safety and Efficacy of Lurasidone With Different Initiation Dose in Chinese Acute Phase Patients With Schizophrenia
The Safety and Efficacy of Lurasidone With Different Initiation Dose in Chinese Acute Phase Patients With Schizophrenia: A Multi-Center, Prospective, Open-Label Study for 6 Weeks
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 200 (actual)
- Sponsor
- Sumitomo Pharma (Suzhou) Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety and efficacy of Lurasidone initiated with 40mg and 80mg in treatment with acute phase patients with schizophrenia
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lurasidone | Oral administration with a meal or within 30 min after eating in the evening. The dosage could be adjusted from Day 8. |
Timeline
- Start date
- 2021-08-16
- Primary completion
- 2023-04-16
- Completion
- 2023-06-16
- First posted
- 2021-08-18
- Last updated
- 2024-04-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05011669. Inclusion in this directory is not an endorsement.